Adverse Events From Semaglutide Seen in the ED Usually GI-Related
TUESDAY, April 15, 2025 -- The rate of emergency department visits for adverse events among patients dispensed semaglutide is low, with most visits involving gastrointestinal effects, according to a research letter published online April 8 in the Annals of Internal Medicine.
Maribeth C. Lovegrove, M.P.H., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues characterized and quantified U.S. emergency department visits that clinicians attributed to semaglutide adverse events using data from the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project.
The researchers found that based on 551 cases, there were an estimated 24,499 emergency department visits attributed to semaglutide adverse events in 2022 through 2023 (mean patient age, 50.9 years; 73.2 percent female); 82.6 percent were in 2023. In 81.7 percent of visits, semaglutide was the only medication implicated and was almost always in injectable form (94.0 percent); medication errors were involved in 9.0 percent of visits. Emergency department visits most often involved gastrointestinal effects, hypoglycemia, and allergic reactions (69.3, 16.5, and 5.5 percent, respectively); the gastrointestinal symptoms most commonly reported were nausea/vomiting, abdominal pain, and diarrhea (57.6, 25.1, and 12.2 percent, respectively). Hospitalization was required in 37.6 and 15.0 percent of emergency department visits for hypoglycemia and for gastrointestinal effects, respectively.
"Clinicians could counsel patients when initiating semaglutide about the potential for severe gastrointestinal adverse effects and adjust coprescribed antidiabetic medications to decrease hypoglycemia risk," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Metabolic Surgery Has Greater Long-Term Benefits Than GLP-1 Receptor Agonists
WEDNESDAY, Oct. 1, 2025 -- People with obesity and type 2 diabetes who undergo metabolic surgery live longer and face fewer serious health problems compared with patients treated...
Patients With Extreme Obesity Face Limitations to Accessing Specialty Care
TUESDAY, Sept. 30, 2025 -- Patients weighing more than 450 lb face considerable limitations when attempting to access specialty care, according to a research letter published...
GLP-1 Receptor Agonists Tied to Reduced Mortality in Patients With Psoriasis
TUESDAY, Sept. 30, 2025 -- Patients with psoriasis treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have better long-term outcomes compared with those taking...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.